This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEXINGTON, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the following upcoming conferences:
Deutsche Bank 2013 BioFEST – Monday, December 2, 2013 at 3:25 p.m. ET in Boston. A corresponding webcast of this presentation can be accessed by visiting:
Both presentations will be held using a "fireside chat" format in which Dr. Ali Fattaey, President and Chief Operating Officer, will provide a brief overview of the Company's business strategy and pipeline of targeted cancer drug candidates, after which an equity analyst will moderate a question and answer session.
The presentations will be archived shortly after the live events and available for 30 days following the conference. In addition, they will be available for 30 days on the Investor Relations section of the Curis website at
About Curis, Inc.
Curis is an oncology-focused drug development company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs, including CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at
CONTACT: Mani Mohindru, Ph.D.
Vice President, Corporate Strategy and Investor Relations
Michael P. Gray
Chief Financial Officer